The utilization of basal luteinizing hormone in combination with the basal luteinizing hormone and follicle-stimulating hormone ratio as a diagnostic tool for central precocious puberty in girls
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Intravenous gonadotropin-releasing hormone (IV GnRH) testing is the gold standard for confirming a central precocious puberty (CPP) diagnosis. However, this test is not widely available commercially. Therefore, our study aim was to establish cutoff values for basal gonadotropin level and gonadotrophin responses to a 100-μg subcutaneous IV GnRH test that can distinguish between CPP and premature thelarche (PT) to discover a simple method to detect CPP. Methods: Girls between the ages of 6 and 8 years who attended the pediatric endocrinology outpatient clinic at our tertiary hospital between 2019 and 2022 were included in this study. They were evaluated for breast development, and a subcutaneous 100-μg GnRH test was administered by measuring the luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in blood samples at baseline and then 30, 60, 90, and 120 minutes after injection. CPP is characterized by increased height velocity, advanced bone age, and progression of breast development. The cutoff value for diagnosis of CPP was determined using a receiver operating characteristic (ROC) analysis. Results: In 86 Thai girls (56 with CPP and 30 with PT), the ROC analysis showed 71.4% and 100% sensitivity and specificity, respectively, for basal LH (cutoff ≥ 0.2 IU/L) plus the basal LH/FSH ratio (cutoff ≥ 0.1). The optimal cutoff values for peak LH (cutoff ≥ 7 IU/L) demonstrated a sensitivity of 94.6% and a specificity of 100%, whereas the LH value at 30 and 60 minutes after injection (cutoff ≥ 6 IU/L) demonstrated sensitivities of 92.9% and 94.6% and a specificity of 100%, respectively Conclusion: Combining the basal LH (cutoff: 0.2 IU/L) and the basal LH/FSH ratio (cutoff: 0.1) can easily and cost-effectively diagnose CPP in a girl in breast Tanner stage II.
Abstract
Purpose: Intravenous gonadotropin-releasing hormone (IV GnRH) testing is the gold standard for confirming a central precocious puberty (CPP) diagnosis. However, this test is not widely available commercially. Therefore, our study aim was to establish cutoff values for basal gonadotropin level and gonadotrophin responses to a 100-μg subcutaneous IV GnRH test that can distinguish between CPP and premature thelarche (PT) to discover a simple method to detect CPP. Methods: Girls between the ages of 6 and 8 years who attended the pediatric endocrinology outpatient clinic at our tertiary hospital between 2019 and 2022 were included in this study. They were evaluated for breast development, and a subcutaneous 100-μg GnRH test was administered by measuring the luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in blood samples at baseline and then 30, 60, 90, and 120 minutes after injection. CPP is characterized by increased height velocity, advanced bone age, and progression of breast development. The cutoff value for diagnosis of CPP was determined using a receiver operating characteristic (ROC) analysis. Results: In 86 Thai girls (56 with CPP and 30 with PT), the ROC analysis showed 71.4% and 100% sensitivity and specificity, respectively, for basal LH (cutoff ≥ 0.2 IU/L) plus the basal LH/FSH ratio (cutoff ≥ 0.1). The optimal cutoff values for peak LH (cutoff ≥ 7 IU/L) demonstrated a sensitivity of 94.6% and a specificity of 100%, whereas the LH value at 30 and 60 minutes after injection (cutoff ≥ 6 IU/L) demonstrated sensitivities of 92.9% and 94.6% and a specificity of 100%, respectively Conclusion: Combining the basal LH (cutoff: 0.2 IU/L) and the basal LH/FSH ratio (cutoff: 0.1) can easily and cost-effectively diagnose CPP in a girl in breast Tanner stage II.
참고문헌 (24)
- Abreu AP, "Pubertal development and regulation", Lancet Diabetes Endocrinol, 4, pp.254~264 (2016)
- Parent AS, "The timing of normal puberty and the age limits of sexual precocity : variations around the world, secular trends, and changes after migration", Endocr Rev, 24, pp.668~693 (2003)
- "Precocious puberty" (2023)[URL]
- Chen M, "Central precocious puberty : update on diagnosis and treatment", Paediatr Drugs, 17, pp.273~281 (2015)
- Fudge E, "Endocrinology and diabetes: case studies, questions and commentaries", pp.185~196 (2022), Springer
- Yang H, "The association between family impact and health-related quality of life of children with idiopathic central precocious puberty in Chongqing, China", Health Qual Life Outcomes, 19, pp.171~ (2021)
- Carel JC, "Consensus statement on the use of gonadotropin-releasing hormone analogs in children", Pediatrics, 123, pp.e752~e762 (2009)
- 정모경, "Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone", Annals of Pediatric Endocrinology & Metabolism, 19(4), pp.214~219 (2014), 대한소아내분비학회
- Kletter GB, "A pediatrician's guide to central precocious puberty", Clin Pediatr(Phila), 54, pp.414~424 (2015)
- Khokhar A, "Premature thelarche", Pediatr Ann, 47, pp.12~15 (2018)
- Eugster EA, "Update on precocious puberty in girls", J Pediatr Adolesc Gynecol, 32, pp.455~459 (2019)
- Wankanit S, "Basal serum luteinising hormone cut-off, and its utility and cost-effectiveness for aiding the diagnosis of the onset of puberty in girls with early stages of breast development", Clin Endocrinol(Oxf), 92, pp.46~54 (2020)
- Poomthavorn P, "Subcutaneous gonadotropin-releasing hormone agonist(triptorelin)test for diagnosing precocious puberty", Horm Res, 72, pp.114~119 (2009)
- Freire AV, "High diagnostic accuracy of subcutaneous Triptorelin test compared with GnRH test for diagnosing central precocious puberty in girls", Clin Endocrinol(Oxf), 78, pp.398~404 (2013)
- Bangalore Krishna K, "Use of gonadotropin-releasing hormone analogs in children : update by an international consortium", Horm Res Paediatr, 91, pp.357~372 (2019)
- Greulich WW, "Radiographic atlas of skeletal development of the hand and wrist" (1959), Stanford University Press
- Borges MF, "Premature thelarche clinical and laboratorial", Endocrinol Metab, 52, pp.93~100 (2008)
- Lee PA, "laboratory monitoring of children with precocious puberty", Pediatr Adolesc Med, 148, pp.369~376 (1994)
- Parker KL, "Depot leuprolide acetate dosage for sexual precocity", Endocrinol Metab, 73, pp.50~52 (1991)
- Neely EK, "Normal ranges for immunochemiluminometric gonadotropin assays", J Pediatr, 127, pp.40~46 (1995)
- Neely EK, "Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty", J Pediatr, 127, pp.47~52 (1995)
- Houk CP, "Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls", Pediatrics, 123, pp.1059~1063 (2009)
- Harrington J, "Use of local data to enhance uptake of published recommendations : an example from the diagnostic evaluation of precocious puberty", Arch Dis Child, 99, pp.15~20 (2014)
- Resende EA, "Assessment of basal and gonadotropinreleasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children", J Clin Endocrinol Metab, 92, pp.1424~1429 (2007)